Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-emptive tocilizumab in hypoxic COVID-19 patients
NL-OMON49824Phase 2Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial in coronavirus disease 2019 (COVID-19) comparing Pre-emptive tocilizumab with Control / standard of care (2 arms). Primary endpoint: 30-day mortality. Started Apr 2020; status: active, not recruiting.
02
Drugs
tocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON49824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49824.